Search
Pliant Therapeutics Inc
PLRXAdd to Watchlist
1.090USD
+0.010+0.93%
Close 07-24 16:00（ET）Quotes delayed by 15 min
67.49MMarket Cap
LossP/E TTM
Earnings Forecast
Currency: USD Updated: 2026-07-24The current earnings forecast score of Pliant Therapeutics Inc is 6.00, ranking 131 out of 155 in the Pharmaceuticals industry. The average price target is 3.50, with a high of 4.00 and a low of 2.00.
Analyst Rating
Based on
5
analysts
Hold
Current Rating
2.500
Target Price
+131.48%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
160
Total
6
Median
9
Average
Company name
Ratings
Analysts
Pliant Therapeutics Inc
PLRX
5
Amgen Inc
AMGN
38
Biogen Inc
BIIB
38
Eli Lilly and Co
LLY
34
AbbVie Inc
ABBV
34
Pfizer Inc
PFE
32
1
2
3
...
32
Support & Resistance
Relevant data have not been disclosed by the company yet.
Financial Forecasting
EPS
Revenue
Net Profit
EBIT
Forecast
Actual
FAQs
What is Pliant Therapeutics Inc's price target?
Analysts forecast that Pliant Therapeutics Inc's price target is USD 3.50, with the highest forecast at USD 4.00 and the lowest forecast at USD 2.00.
How have Pliant Therapeutics IncPLRX's recent earnings per share performed?
The market expectation was USD -0.32, while Pliant Therapeutics IncPLRX's earnings per share (EPS) for the previous quarter was USD -0.38. EPS for the next quarter is expected at USD -0.34.
What is the analyst rating for Pliant Therapeutics Inc?
Based on the ratings of Pliant Therapeutics Inc's stock from 5 analysts, most analysts support a signal_hold trend. After considering the opinions of other analysts, we ultimately rate Apple's stock as signal_hold. Please note that this is not trading advice. You still need to conduct your own analysis.